Mode
Text Size
Log in / Sign up
N/A N=32 Randomized Supportive Care

Randomized Clinical Trial on Transanal Irrigation

Low Anterior Resection Syndrome

Enrolled (actual)
32
Serious AEs
0.0%
Results posted
Jul 2024
Primary outcome: Primary: LARS Score — 21.3; 32.2 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Peristeen cone catheter (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Coloplast A/S
Primary completion
Dec 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
LARS Score
21.3; 32.2
SECONDARY
Number of Subjects With Major LARS
5; 10
SECONDARY
FIQL Score - Scale 1 Lifestyle, Modified American Society for Colorectal Surgeons Questionnaire
3.10; 2.60
SECONDARY
FIQL Score - Scale 2 Coping/Behavior, Modified American Society for Colorectal Surgeons Questionnaire
2.95; 2.37
SECONDARY
FIQL Score - Scale 3 Depression/Self-perception, Modified American Society for Colorectal Surgeons Questionnaire
3.41; 3.23
SECONDARY
FIQL Score - Scale 4 Embarrassment , Modified American Society For Colorectal Surgeons Questionnaire
2.98; 2.76
SECONDARY
EQ-5D-5L - Utility Score
0.92; 0.88
SECONDARY
EQ-5D-5L - VAS Score
82.8; 71.4
SECONDARY
Satisfaction With Treatment
8.6; 5.9

Summary

Objective The primary objective is to demonstrate superiority of the Peristeen cone catheter compared to standard of care. The secondary objective is to investigate quality of life and different benefits and aspects of treatment and satisfaction with the Peristeen cone catheter. Design of the investigation This is a randomised, open-label, parallel investigation comparing the Peristeen cone catheter with standard of care in subjects with major LARS (LARS score ≥ 30). Each subject will be enrolled for a study duration of 12 weeks. Subjects will be randomized to the treatments stratified by neo-adjuvant radiotherapy. The comparator in this study will be current standard of care for patients with LARS which is conservative bowel management. This is defined as: Supportive therapy according to the individual treatment protocols available at each participating site. Primary endpoint and secondary endpoints Primary endpoint: • LARS score, obtained from the LARS score questionnaire* Secondary endpoints: * Number of subjects with Major LARS* * FIQL Score - scale 1, Modified American Society for Colorectal Surgeons Questionnaire* * FIQL Score - scale 2, Modified American Society for Colorectal Surgeons Questionnaire* * FIQL Score - scale 3, Modified American Society for Colorectal Surgeons Questionnaire* * FIQL Score - scale 4, Modified American Society for Colorectal Surgeons Questionnaire* * EQ-5D-5L - utility score* * EQ-5D-5L - VAS score (scale 0-10 cm)* * Satisfaction with treatment (scale 0-10 cm)* * Number of adverse events* *All endpoints are measured per subject at study completion

Eligibility Criteria

Inclusion Criteria

  • Be at least 18 years of age and have full legal Capacity
  • Have given written informed consent
  • Be mental and physical capable to perform transanal irrigation with cone catheter
  • Have a LARS score ≥ 30 after rectal resection
  • Be treated according to individual treatment protocol for conservatory bowel management at participating site
  • Have proof of complete healing of the anastomosis by endoscopy or radiology before stoma closure
  • At least 3-months from last surgery in colorectum
  • Be evaluated to be suitable for transanal Irrigation procedure with a cone catheter by endoscopy, defecography or comparable procedure

Exclusion Criteria

  • Active/recurrent colorectal cancer
  • Leaking anastomosis
  • Known anal or colorectal stenosis
  • Within 4 weeks of endoscopic polypectomy
  • Ischaemic colitis
  • Acute inflammatory bowel disease
  • Acute diverticulitis
  • Current or planned pregnancy
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04586634). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search